

Pliant Therapeutics posts interim Phase 1 data showing antitumor activity and durable responses for PLN-101095 in ICI-refractory advanced cancer patients.
You can purchase shares of Pliant Therapeutics (NASDAQ:PLRX) through any online brokerage.
Other companies in Pliant Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Pliant Therapeutics has a consensus price target of $3.50.
The stock price for Pliant Therapeutics (NASDAQ: PLRX) is $0.95 last updated October 26, 2026 at 8:42 AM EDT.
There are no upcoming dividends for Pliant Therapeutics.
Pliant Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Pliant Therapeutics.
Pliant Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel...